Brenda Grogan

St. Vincent's University Hospital
Dublin, L, Ireland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Acute Pulmonary Exacerbation Phenotypes in Patients with Cystic Fibrosis.

Acute Pulmonary Exacerbation Phenotypes in Patients with Cystic Fibrosis.

Journal: Annals of the American Thoracic Society

Published: June 17, 2022

Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections.

Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections.

Journal: mBio

Published: December 14, 2021

Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease.

Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease.

Journal: The European respiratory journal

Published: August 09, 2020

Ivacaftor modifies cystic fibrosis neutrophil phenotype in subjects with R117H residual function CFTR mutations.

Ivacaftor modifies cystic fibrosis neutrophil phenotype in subjects with R117H residual function CFTR mutations.

Journal: The European respiratory journal

Published: June 04, 2020

CFTR Modulator Therapy Enhances Peripheral Blood Monocyte Contributions to Immune Responses in People With Cystic Fibrosis.

CFTR Modulator Therapy Enhances Peripheral Blood Monocyte Contributions to Immune Responses in People With Cystic Fibrosis.

Journal: Frontiers in pharmacology

Published: May 28, 2020

Changes in fecal microbiota with CFTR modulator therapy: A pilot study.

Changes in fecal microbiota with CFTR modulator therapy: A pilot study.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: May 13, 2020

Ivacaftor decreases monocyte sensitivity to interferon-γ in people with cystic fibrosis.

Ivacaftor decreases monocyte sensitivity to interferon-γ in people with cystic fibrosis.

Journal: ERJ open research

Published: December 03, 2019

Ivacaftor-induced sweat chloride reductions correlate with increases in airway surface liquid pH in cystic fibrosis.

Ivacaftor-induced sweat chloride reductions correlate with increases in airway surface liquid pH in cystic fibrosis.

Journal: JCI insight

Published: April 04, 2018

Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections.

Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections.

Journal: American journal of respiratory and critical care medicine

Published: February 22, 2017

Acute administration of ivacaftor to people with cystic fibrosis and a G551D-CFTR mutation reveals smooth muscle abnormalities.

Acute administration of ivacaftor to people with cystic fibrosis and a G551D-CFTR mutation reveals smooth muscle abnormalities.

Journal: JCI insight

Published: May 10, 2016

Ivacaftor-Induced Proteomic Changes Suggest Monocyte Defects May Contribute to the Pathogenesis of Cystic Fibrosis.

Ivacaftor-Induced Proteomic Changes Suggest Monocyte Defects May Contribute to the Pathogenesis of Cystic Fibrosis.

Journal: American journal of respiratory cell and molecular biology

Published: April 02, 2016

Ivacaftor as salvage therapy in a patient with cystic fibrosis genotype F508del/R117H/IVS8-5T.

Ivacaftor as salvage therapy in a patient with cystic fibrosis genotype F508del/R117H/IVS8-5T.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: January 12, 2015

Showing 1-12 of 12

Last Updated: 09/26/2026